WilliamHMeyerMD

PubMed

• 3 citations
  The significance of margins in pediatric Non-Rhabdomyosarcoma soft tissue sarcomas: Consensus on surgical margin definition harmonization from the INternational Soft T...
  Monika Sparber-Sauer, Andrea Ferrari, Sheri L Spunt, Christian Vokuhl, Dana Casey, Timothy B Lautz, William H Meyer, David O Walterhouse, Kristian W Pajtler, Rita Alag...> ;Cancer Medicine. 2023 May 1
• 12 citations
  The treatment approach to pediatric non-rhabdomyosarcoma soft tissue sarcomas: a critical review from the INternational Soft Tissue SaRcoma ConsorTium.
  Andrea Ferrari, Daniel Orbach, Monika Sparber-Sauer, David O Walterhouse, Kristian W Pajtler, William H Meyer, Sheri L Spunt, Aaron R Weiss> ;European Journal of Cancer. 2022 Jul 1
• 1 citations
  A Case of Cyclic Neutropenia and Associated Amyloidosis.
  Chibuzo Ilonze, Kari M. Galipp, Teresa Scordino, William H. Meyer, Ashley Baker> ;Journal of Pediatric Hematology/oncology. 2021 Jul 1
• 9 citations
  Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
  Holly L Pacenta, Wendy Allen-Rhoades, David M. Langenau, Peter J. Houghton, Charles Keller, Christine M. Heske, Michael D. Deel, Corinne M. Linardic, Jack F. Shern, El...> ;Journal of Clinical Medicine. 2021 Apr 1
• 18 citations
  Metabolic response as assessed by 18 F-fluorodeoxyglucose positron emission tomography-computed tomography does not predict outcome in patients with intermediate- or h...
  Douglas J. Harrison, Yueh-Yun Chi, Jing Tian, Pooja Hingorani, Leo Mascarenhas, Geoffrey McCowage, Brenda J. Weigel, Rajkumar Venkatramani, Suzanne L. Wolden, Torunn I...> ;Cancer Medicine. 2021 Feb 1
• 62 citations
  Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with o...
  Aaron R. Weiss, Yen-Lin Chen, Thomas J. Scharschmidt, Yueh Yun Chi, Jing Tian, Jennifer O. Black, Jessica L. Davis, Julie C. Fanburg-Smith, Eduardo Zambrano, James R. ...> ;The Lancet. Oncology. 2020 Jul 20
• 66 citations
  A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
  Sheri L. Spunt, Lynn Million, Yueh-Yun Chi, James R. Anderson, Jing Tian, Emily Hibbitts, Cheryl M. Coffin, M. Beth McCarville, R. Lor Randall, David M. Parham, Jennif...> ;The Lancet. Oncology. 2020 Jan 1
• 1 citations
  Improving Outcomes for Patients With Pulmonary Metastatic Ewing Sarcoma.
  William H. Meyer> ;Journal of Clinical Oncology. 2019 Oct 21
• 77 citations
  Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Ch...
  Emily Hibbitts, Yueh-Yun Chi, Douglas S. Hawkins, Frederic G. Barr, Julie A. Bradley, Roshni Dasgupta, William H. Meyer, David A. Rodeberg, Erin R. Rudzinski, Sheri L....> ;Cancer Medicine. 2019 Oct 1
• 5 citations
  Maintenance chemotherapy in rhabdomyosarcoma: the new standard of care
  William H. Meyer> ;The Lancet. Oncology. 2019 Sep 24
• 57 citations
  Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group.
  Leo Mascarenhas, Yueh-Yun Chi, Pooja Hingorani, James R. Anderson, Elizabeth Lyden, David A. Rodeberg, Daniel J. Indelicato, Simon C. Kao, Roshni Dasgupta, Sheri L. Sp...> ;Journal of Clinical Oncology. 2019 Sep 12
• 20 citations
  Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group
  Leo Mascarenhas, Elizabeth R. Lyden, Philip P. Breitfeld, David O. Walterhouse, Sarah S. Donaldson, David A. Rodeberg, David M. Parham, James R. Anderson, William H. M...> ;Cancer. 2019 Aug 1
• 55 citations
  The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma...
  Suman Malempati, Brenda J. Weigel, Yueh-Yun Chi, Jing Tian, James R. Anderson, David M. Parham, Lisa A. Teot, David A. Rodeberg, Torunn I. Yock, Barry L. Shulkin, Sher...> ;Cancer. 2019 Jan 15
• 17 citations
  Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Co...
  David O. Walterhouse, Donald A. Barkauskas, David R. Hall, Andrea Ferrari, Gian Luca De Salvo, Ewa Koscielniak, Michael C.G. Stevens, Hélène Martelli, Guido Seitz, Dav...> ;Journal of Clinical Oncology. 2018 Oct 23
• 109 citations
  Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report Fro...
  Douglas S. Hawkins, Yueh Yun Chi, James R. Anderson, Jing Tian, Carola A.S. Arndt, Lisa Bomgaars, Sarah S. Donaldson, Andrea Hayes-Jordan, Leo Mascarenhas, Mary Beth M...> ;Journal of Clinical Oncology. 2018 Aug 9
• 56 citations
  Consensus and controversies regarding the treatment of rhabdomyosarcoma.
  Scott C. Borinstein, Diana Steppan, Masanori Hayashi, David M. Loeb, Michael S. Isakoff, Odion Binitie, Andrew S. Brohl, Julia A. Bridge, Mark J. Stavas, Eric T. Shino...> ;Pediatric Blood & Cancer. 2018 Feb 1
• 64 citations
  Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
  Erin R. Rudzinski, James R. Anderson, Yueh-Yun Chi, Julie M. Gastier-Foster, Caroline Astbury, Frederic G. Barr, Stephen X. Skapek, Douglas S. Hawkins, Brenda J. Weige...> ;Pediatric Blood & Cancer. 2017 May 18
• 56 citations
  Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tiss...
  David O. Walterhouse, Alberto S. Pappo, Jane L. Meza, John C. Breneman, Andrea Hayes-Jordan, David M. Parham, Timothy P. Cripe, James R. Anderson, William H. Meyer, Do...> ;Cancer. 2017 Jun 15
• 18 citations
  Patterns of chemotherapy-induced toxicities and outcome in children and adolescents with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
  Abha A. Gupta, Yueh-Yun Chi, James R. Anderson, Elizabeth Lyden, Brenda J. Weigel, Carola A.S. Arndt, William H. Meyer, Abby R. Rosenberg, Douglas S. Hawkins> ;Pediatric Blood & Cancer. 2017 Mar 23
• 1 citations
  Regarding Beau.
  William H Meyer> ;Journal of Clinical Oncology. 2016 Aug 1
• 9 citations
  Risk-Based Therapy for Localized Osteosarcoma.
  Rajkumar Venkatramani, Jeffrey C. Murray, Lee J. Helman, William H. Meyer, M. John Hicks, Robert A. Krance, Ching C. Lau, Eunji Jo, Murali Chintagumpala> ;Pediatric Blood & Cancer. 2016 Mar 1
• 21 citations
  Prognostic Factors for Outcome in Localized Extremity Rhabdomyosarcoma. Pooled Analysis from Four International Cooperative Groups
  Odile Oberlin, Annie Rey, Kenneth L.B. Brown, Gianni Bisogno, Ewa Koscielniak, Michael C. Stevens, Douglas S. Hawkins, William H. Meyer, Trang H. La, Modesto Carli, Ja...> ;Pediatric Blood & Cancer. 2015 Dec 1
• 126 citations
  Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Pati...
  Brenda J. Weigel, Elizabeth R. Lyden, James R. Anderson, William H. Meyer, David M. Parham, David A. Rodeberg, Jeff M. Michalski, Douglas S. Hawkins, Carola A.S. Arndt> ;Journal of Clinical Oncology. 2016 Sep 19
• 13 citations
  Progress Born From a Legacy of Collaboration
  Melissa M. Hudson, William H. Meyer, Ching-Hon Pui> ;Journal of Clinical Oncology. 2015 Sep 20
• 86 citations
  Shorter-Duration Therapy Using Vincristine, Dactinomycin, and Lower-Dose Cyclophosphamide With or Without Radiotherapy for Patients With Newly Diagnosed Low-Risk Rhabd...
  David O. Walterhouse, Alberto S. Pappo, Jane L. Meza, John C. Breneman, Andrea Hayes-Jordan, David M. Parham, Timothy P. Cripe, James R. Anderson, William H. Meyer, Do...> ;Journal of Clinical Oncology. 2014 Sep 29
• Join now to see all

Journal Articles

• Mesna excretion and ifosfamide nephrotoxicity in children.  
  Goren MP, Pratt CB, Meyer WH, Wright PK, Dodge RK, Viar MJ, Cancer Res
• Ifosfamide in pediatric malignant solid tumors.  
  Pratt CB, Douglass EC, Etcubanas EL, Goren MP, Green AA, Hayes FA, Horowitz ME, Meyer WH, Thompson EI, Wilimas JA, Cancer Chemother Pharmacol
• Malignant melanoma in children: Its management and prognosis.  
  Rao BN, Hayes FA, Pratt CB, Fleming ID, Kumar APM, Lobe T, Dilawari R, Meyer W, Parham D, Custer MD, J Pediatr Surg
• Sarcomas (other than Ewing's) of flat bones in children and adolescents: A clinicopathologic study.  
  Kellie SJ, Pratt CB, Parham DM, Fleming ID, Meyer WH, Rao BN, Cancer
• Results in patients with cranial parameningeal sarcoma and metastases (Stage 4) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols II-IV.  
  Raney B, Anderson J, Breneman J, Donaldson SS, Huh W, Maurer H, Michalski J, Qualman S, Ulrich F, Wharam M, Meyer W, Pediatr Blood Cancer
• Development and characterization of pediatric osteosarcoma xenografts.  
  Meyer WH, Houghton JA, Houghton PJ, Webber BL, Douglass EC, Look AT, Cancer Res
• Prognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groups.  
  Oberlin O, Rey A, Lyden E, Bisogno G, Stevens MC, Meyer WH, Carli M, Anderson JR, J Clin Oncol
• Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors.  
  Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK, J Clin Oncol
• Accumulation, intracellular metabolism, and antitumor activity of high- and low-dose methotrexate in human osteosarcoma xenografts.  
  Meyer WH, Loftin SK, Houghton JA, Houghton PJ, Cancer Communications
• A second nonrandom translocation, der(16)t(1;16)(q21;q13), in Ewing sarcoma and peripheral neuroectodermal tumor.  
  Douglass EC, Rowe ST, Valentine M, Parham D, Meyer WH, Thompson EI, Cytogenet Cell Genet
• Use of MR imaging to assess results of chemotherapy for Ewing sarcoma.  
  Lemmi MA, Fletcher BD, Marina NM, Slade W, Parham DM, Jenkins JJ, Meyer WH, AJR
• Metastatic small cell tumor of bone with "true" rosettes and glial fibrillary acidic protein positivity.  
  Parham DM, Thompson E, Fletcher B, Meyer WH, Am J Clin Path
• Changing patterns of pulmonary metastases with adjuvant chemotherapy in patients with osteosarcoma: Results from the multi-institutional osteosarcoma study.  
  Goorin AM, Shuster JJ, Baker A, Horowitz M, Meyer WH, Link MP, J Clin Oncol
• Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive ...  
  Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM, Meyer WH, Crist WM, J Clin Oncol
• Ifosfamide, Fanconi syndrome, and rickets.  
  Pratt CB, Meyer WH, Jenkins JJ, McKay CP, Wyatt RJ, J Clin Oncol
• Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy.  
  Arai Y, Kun LE, Brooks MT, Fairclough DL, Fontanesi J, Meyer WH, Hayes FA, Thompson E, Rao BN, Int J Radiat Oncol Biol Phys
• Phase I study of flavone acetic acid (NSC 347512, LM 975) in patients with pediatric malignant solid tumors.  
  Pratt CB, Relling MV, Meyer WH, Douglass EC, Kellie SJ, Avery L, Am J Clin Oncol
• Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: Updated results of the Multi-Institutional Osteosarcoma Study.  
  Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J, Clin Orthop
• Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.  
  Relling MV, Cherrie J, Schell MJ, Petros WP, Meyer WH, Evans WE, Clin Pharmcol Ther
• Osteosarcoma: Good news despite crude tools. (Editorial).  
  Simone JV, Meyer WH, Link MP, J Clin Oncol
• Assessment of osteosarcoma response to preoperative chemotherapy using dynamic flash Gd-DTPA-enhanced MR mapping.  
  Hanna SL, Parham DM, Fairclough DL, Meyer WH, Le AH, Fletcher BD, Invest Radiol
• Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone.  
  Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, Fletcher B, Pratt CB, J Clin Oncol
• Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis.  
  Marina NM, Pratt CB, Rao BN, Shema S, Meyer WH, Cancer
• Use of GM-CSF in children after high-dose chemotherapy.  
  Furman WL, Fairclough D, Cain AM, Arnold BA, Pratt CB, Meyer WH, Crist W, Med Pediatr Oncol
• Phase I Study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors.  
  Marina NM, Rodman J, Shema SJ, Bowman LC, Douglass E, Furman W, Santana VM, Hudson M, Wilimas J, Meyer W, Madden T, Pratt C, J Clin Oncol
• Join now to see all

Books/Book Chapters

• Osteosarcoma: clinical features and evolving surgical and chemotherapeutic strategies. 
  Chapter: Pediatric Clinics of North America 
  Page 317 - 348Meyer WH, Malawer MMEditors: Horowitz ME, Pizzo PA.WB Saunders, Philadelphia
• Principles of total care: Rehabilitation. 
  Chapter: Clinical Pediatric Oncology. Clinical Pediatric Oncology 
  Page 285 - 294Meyer WHEditors: Fernbach DJ, Vietti TJ.Mosby Year Book, St. LouisEdition 4,
• Ewing's sarcoma. 
  Chapter: Rudolph's Pediatrics 
  Page 1205 - 1207Meyer WH, Thompson EIEditors: Rudolph AM.Appleton and Lange, Norwalk, ConnecticutEdition 19,
• Recent developments in genetic mechanisms, assessment, and treatment of osteosarcoma. 
  Chapter: Rudolph's Pediatrics 
  Page 689 - 693Meyer WH
• Osteosarcoma. 
  Chapter: Rudolph's Pediatrics 
  Page 1207 - 1210Meyer WH, Thompson EIEditors: Rudolph AM.Appleton & Lange, Norwalk, ConnecticutEdition 19,
• Effects of radiation therapy and chemotherapy on hearing. 
  Chapter: Late effects of treatment for childhood cancer 
  Page 7 - 10McHaney V, Kovnar E, Meyer W, Furman W, Schell M, Kun LWiley-Liss, Inc
• Osteosarcoma Studies at St. Jude Children's Research Hospital from 1968 through 1990. 
  Chapter: Controversies and Current Practice 
  Page 323 - 326Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming IDEditors: Humphrey GB.Pediatric Oncology Kluwer Academic Publishers
• Identification of new chemotherapeutic agents for treatment of childhood solid tumors with a focus on sarcomas. 
  Chapter: Frontiers of Osteosarcoma Research 
  Page 105 - 115Houghton PJ, Meyer WH, Look AT, Houghton JA
• Osteosarcoma. 
  Chapter: Current therapy in oncology 
  Pratt CB and Meyer WHEditors: Foley JF, Armitage JO, Vose Julie M.W.B. Saunders Co, Orlando, FL
• Neoplasms of Bone. 
  Chapter: Nelson Textbook of Pediatrics 
  Page 1467 - 1470Meyer WilliamEditors: Behrman E, Kliegman R, Arvin M, Nelson W.W.B. Saunders Co, Philadelphia PAEdition 15,
• Ewing sarcoma/peripheral neuroepithelioma. 
  Chapter: Rudolph's Pediatrics, 20th edition 
  Page 1290 - 1292Meyer WHEditors: Rudolph AM, Hoffman JIE, Rudolph CD.Appleton & Lange, Stamford, Connecticut
• Osteosarcoma. 
  Chapter: Rudolph's Pediatrics 
  Page 1292 - 1295Pratt CB, Meyer WHEditors: Rudolph AM, Hoffman JIE, Rudolph CD.Appleton &Lange, Stamford Connecticut
• Soft Tissue Sarcomas (142d) for Section 37 Pediatric Oncology. 
  Chapter: Holland & Frei Cancer Medicine 6 
  Page 2377 - 2383Meyer WHEditors: Kufe DW, Pollock RE, Wiechselbaum RR, Bast TC, Gansler TS, Holland JF, and Frei E III.BC Decker Inc, Hamilton, Ontario
• Soft tissue sarcomas of childhood. 
  Chapter: Cancer Treatment Reviews 
  Page 269 - 280Meyer WH, Spunt SL
• Rhabdomyosarcoma and the undifferentiated sarcomas. 
  Chapter: Principles and Practice of Pediatric Oncology 
  Page 971 - 1001Wexler LH, Meyer WH, Helman LJEditors: Pizzo PA and Poplack DG.Lippincott William Wilkins, Publishers, Philadephia, PAEdition 5,
• Soft Tissue Sarcomas of Childhood (142k) for Section 37 Pediatric Oncology 
  Chapter: Holland & Frei Cancer Medicine 7 
  Page 2007 - 2012Meyer WHEditors: Kufe DW, Bast RC, Hait WN, Hong WK, Pollock RE, Wiechselbaum RR, TS, Holland JF, and Frei E III.BC Decker Inc, Hamilton, Ontario
• Soft Tissue Sarcomas. 
  Chapter: Cancer in Children and Adolescents 
  Meyer WH, Stevens MCG, Cripe TEditors: Carroll WL and Findlay JL.Jones and Bartlett, Sudbury MA
• Rhabdomyosarcoma and the undifferentiated sarcomas. 
  Chapter: Principles and Practice of Pediatric Oncology 
  Wexler LH, Meyer WH, Helman LJEditors: Pizzo PA and Poplack DG.Lippincott William Wilkins, Philadephia, PAEdition 6,
• Late effects of cancer therapy. 
  Chapter: Complications of cancer diagnosis and management. 
  Meyer WH, Leventhal BGEditors: Abeloff M.Baltimore: Johns Hopkins University Press, Chapter XV
• Hematologic emergencies. 
  Chapter: Pediatric emergency medicine 
  Howard TH, Meyer WHEditors: Ehrlich F, Heldrich FJ, Tepas JJ.Aspen, Rockville, Maryland
• Adjuvant chemotherapy in the treatment of osteosarcoma: Results of the multi-institutional osteosarcoma study. 
  Chapter: Recent concepts in sarcoma treatment 
  Page 283 - 290Link MP, Shuster JJ, Goorin AM, Miser A, Meyer WH, Kingston JE, Belasco J, Baker AR, Ayala AG, Vietti TEditors: Ryan JR, Baker LO.Kluwer Academic
• Use of investigational drugs as initial therapy for childhood solid tumors. 
  Chapter: Hematol Bluttransfus 
  Page 141 - 148Meyer WH, Houghton PJ, Horowitz ME, Etcubanas E, Pratt CB, Hayes FA, Thompson EI, Green AA, Houghton JA, Sandlund JT, Crist WM
• The use of ifosfamide as initial therapy in osteosarcoma. 
  Chapter: Adjuvant therapy of cancer 
  Page 580 - 585Meyer WH, Pratt CB, Schell MJ, Fletcher BD, Marina N, Parham DM, Rao BN, Sandlund JT, Dahl GEditors: Salmon SE.WB Saunders, Philadelphia
• Join now to see all

Abstracts/Posters

• Pharmacokinetics (PD) of topotecan (TPT) in pediatric patients with normal and altered renal function.
  Zamboni WC, Heideman RL, Meyer WH, Gajjar AJ, Crom WR, Stewart CF, ASCO Proceedings
• Glucocorticoid receptors in myeloid maturation.
  Meyer WH, American Society of Hematology
• Functional outcome following limb salvage surgery above the knee.
  Neel M, Rao BN, Meyer W, Pappo A, Kaste SC, Pratt CB, Cremer L, Lynch M, SIOP Vienna Austria
• Familial osteosarcoma, or osteosarcoma as part of a spectrum of familial tumors?
  Pratt CB, Meyer WH, Cain A, Rao BN, ASCO Proceedings
• The student with cancer in the classroom. A workshop for educators.
  Meyer WH, Ellingwood G, Pollard A, American Association for Cancer Education Med Pediatr Oncol
• Curative therapy for osteosarcoma without cisplatin - preliminary results of SJCRH OS-91.
  Meyer WH, Pratt CB, Rao BN, Luo X, Jenkins JJ, Shearer P, Pappo A, Mahmoud H, Neff J, Harper J, ASCO Proceedings
• Increases in actin content and synthesis during HL 60 cell differentiation.
  Meyer WH, American Society of Hematology Blood
• Pharmacokinetically guided dose adjustment reduces variability in topotecan (TPT) systemic exposure in children with solid tumors.
  Zamboni WC, Santana V, Gajjar AJ, Meyer WH, Pappo A, Houghton PJ, Stewart CF, ASCO Proceedings
• Development of locomotive behavior and actin polymerization during HL 60 maturation.
  Meyer WH, Blades S, Howard TH, American Society of Hematology Blood
• Pharmacokinetically-guided use of topotecan (TPT), given (daily x 5) x 2, in children with relapsed solid tumors.
  Santana V, Zamboni W, Gajjar A, Pappo A, Houghton P, Meyer W, Stewart C, ASCO Proceedings
• Hypoxanthine: Guanine phosphoribosyl transferase (HPRT) activity in human osteosarcoma (OS) xeno-grafts.
  Meyer WH, Houghton JA, Houghton PJ, American Association for Cancer Research Proc Am Assoc Cancer Res
• Pulmonary metastases in osteogenic sarcoma (OS): The value of thoracotomy (T).
  Meyer WH, Kumar M, Rao BN, Green AA, Champion J, Schell MJ, Pratt CB, American Society of Clinical Oncology Proc Am Soc Clin Oncol
• Urine enzymes, a sensitive indicator of chemotherapy induced nephrotoxicity.
  Goren M, Wright R, Horowitz M, Jacobsen M, Meyer W, Etcubanas E, Hayes A, Green A, Douglass E, Li J, Pratt C, Proc Am Soc Clin Oncol
• Phase II trial of ifosfa¬mide (IFOS) with mesna in patients with pediatric malignant solid tumors.
  Pratt CB, Horowitz M, Meyer W, Hayes A, Etcubanas E, Douglass E, Thompson E, Wilimas J, Green AA, Proc Am Soc Clin Oncol
• Central nervous system (CNS) toxicity following ifosfamide (IFOS) treatment for children with malignant solid tumors.
  Pratt CB, Green AA, Horowitz M, Meyer W, Douglass E, Thompson E, Etcubanas E, Hayes A, Wilimas J, Choi J, Igarashi M, Proc Am Assoc Cancer Res
• The intrapatient effect of cisplatin therapy on the pharmacokinetics of high ¬dose methotrexate.
  Crom WR, Teresi ME, Meyer WH, Green AA, Evans WE, American College of Clinical Pharmacy Drug Intell Clin Pharm
• Ifosfamide (IFOS)/mesna for pediatric malignant tumors.
  Pratt CB, Horowitz M, Meyer W, Hayes FA, Etcubanas E, Douglass E, Thompson EI, Wilimas J, Green AA, Proc Am Assoc Cancer Res
• Hypoxanthine guanine phosphoriboryl-transferase (HPRT) in human osteosarcomas (OS).
  Meyer WH, Houghton JA, Houghton PJ, Proc Am Assoc Cancer Res
• Response to chemotherapy (CT) of patients with metastatic (M) or unresectable (U) osteosarcoma (OS) at diagnosis and after failing adjuvant chemotherapy.
  Pratt CB, Meyer WH, Proc Am Soc Clin Oncol
• Activity of ifosfamide in metastatic and unresectable osteosarcoma.
  Bowman LC, Meyer WH, Douglass EC, Pratt CB, Proc Am Soc Clin Oncol
• Development and characterization of pediatric osteosarcoma (OS) xenografts.
  Meyer WH, Houghton JA, Houghton PJ, Webber B, Ashmun RA, Proc Am Assoc Cancer Res
• Methotrexate dosage and response in xenografts of human osteosarcoma (OS).
  Meyer WH, Houghton JA, Houghton PJ, Proc Am Assoc Cancer Res
• Osteosarcoma: Pattern of relapse for patients receiving immediate adjuvant chemotherapy compared to patients receiving delayed chemotherapy following relapse.
  Goorin AM, Shuster JJ, Miser A, Meyer WH, Link MP, Proc Am Soc Clin Oncol
• A pediatric phase I/II trial of subcutaneous (SQ)PIXY321 administered after ifosfamide/carboplatin/etoposide (ICE) chemotherapy.
  Furman WL, Marina, Luo X, Arnold B, Pratt C, Bowman LC, Santana V, Garrison L, Meyer W, ASCO Proceedings
• Prognostic indicators for patients with osteosarcoma (OS) treated with adjuvant chemotherapy.
  Liddell RHA, Meyer WH, Dodge RK, Green AA, Pratt CB, Proc Am Assoc Cancer Res
• Join now to see all

Lectures

• Neutrophil Disorders. 
  LeBonheur Grand Rounds
• Osteosarcoma Studies. 
  Pediatric Oncology Branch, NCI
• Use of Investigational Drugs in Childhood Solid Tumors. 
  Wilsede VIII Meeting, Hamburg, Germany
• Pediatrics Review Course. 
  Chicago, IL, 1989
• Bone Tumors, Fall ASCO Educational Symposium. 
  Anaheim, CA
• Ewing's Sarcoma, Future Directions. 
  Pediatric Oncology Branch, NCI
• Up-front Phase II Windows. 
  Childrens Cancer Group Fall Meeting, Dallas, TX
• Bone Tumors - Pediatric Grand Rounds. 
  LeBonheur Children's Hospital, Memphis, TN
• Treatment of Ewing Sarcoma - II Simposio International de Tumores Osseso. 
  Sarcomas dos Tecidos Moles Sao Paulo, Brazil
• Treatment of Osteosarcoma. 
  St. Jude Children's Research Hospital
• Experience at SJCRH with Bone Tumors. 
  InstitutoNacional de Cancer, Rio de Janeiro, Brazil
• SJCRH Experience with Osteosarcoma. 
  Children’s Hospital of Oklahoma Pediatric Grand Rounds
• Upfront Window Trials in Osteosarcoma. 
  Vanderbilt University Department of Pediatrics
• Childhood Cancer. 
  Oklahoma Oncology Nursing Society
• Treatment of Osteogenic Sarcoma. 
  Pediatric Research Conference, 1997; UT Southwestern Children’s Hospital, Dallas, TX
• Pediatric Cancer: When should you worry? 
  24th annual Pediatric Dept. CME Meeting
• Rhabdomyosarcoma and Soft Tissue Sarcomas. 
  Insights, Inc CME Course, sponsored by MD Anderson Cancer Center
• Overview of Childhood Cancer. 
  Southwest Medical Center, Oklahoma City, OK
• Topotecan in Rhabdomyosarcoma – for Topoisomerase I Targeted Drugs in Pediatric Cancer Current and Future Directions. 
  International Symposium. Memphis, TN
• Therapeutic Approaches for Rhabdomyosarcoma. 
  Texas Children’s Cancer Center Research Conference, Houston, Texas
• Prosthetic Management of the Oncology Patient. 
  American Academy of Orthotists and Prosthetists Symposium, Dallas, Texas
• The Intergroup Rhabdomyosarcoma Study Results. 
  Japanese Society for Pediatric Oncology, Tokyo
• Research Directions in rhabdomyosarcoma. 
  Kyoto University, Kyoto
• Soft Tissue Sarcomas in Children and Adolescent. 
  2002 ASCO Education Session, Orlando, FL
• Current IRS/COG Sarcoma Studies. 
  2004 ANZCHOG Annual Meeting, Coolum, Queensland, Australia
• Join now to see all